{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:28:31Z","timestamp":1792164511735,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10072-025-08602-z","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:28:01Z","timestamp":1768202881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"47","author":[{"given":"Ashley","family":"O\u2019Mara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti Pradip","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mammi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Simjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrellos","family":"Ghattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilekha","family":"Kaliki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc Phuong Mai","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1636-0759","authenticated-orcid":false,"given":"Rania A.","family":"Mekary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"8602_CR1","doi-asserted-by":"crossref","unstructured":"Athanasaki A, Melanis K, Tsantzali I, Stefanou MI, Ntymenou S, Paraskevas SG, Kalamatianos T, Boutati E, Lambadiari V, Voumvourakis KI, Stranjalis G, Giannopoulos S, Tsivgoulis G, Paraskevas GP (2022) Type 2 diabetes mellitus as a risk factor for alzheimer\u2019s disease: review and meta-analysis. Biomedicines 10","DOI":"10.3390\/biomedicines10040778"},{"key":"8602_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.17219\/acem\/161734","volume":"32","author":"Z Bi","year":"2023","unstructured":"Bi Z, Wang L, Wang W (2023) Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in alzheimer\u2019s disease: A systematic review and meta-analysis. Adv Clin Exp Med 32:1223\u20131231","journal-title":"Adv Clin Exp Med"},{"key":"8602_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, Garcia-Perez LE, Lakshmanan M, Bethel A, Xavier D, Probstfield J, Riddle MC, Ryden L, Atisso CM, Hall S, Rao-Melacini P, Basile J, Cushman WC, Franek E, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 19:582\u2013590","journal-title":"Lancet Neurol"},{"key":"8602_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, Leon T, Scheltens P (2025) Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic alzheimer\u2019s disease. Alzheimers Res Ther 17:14","journal-title":"Alzheimers Res Ther"},{"key":"8602_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/193229680800200619","volume":"2","author":"SM de la Monte","year":"2008","unstructured":"de la Monte SM, Wands JR (2008) Alzheimer\u2019s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2:1101\u20131113","journal-title":"J Diabetes Sci Technol"},{"key":"8602_CR6","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","volume":"47","author":"A Dei Cas","year":"2024","unstructured":"Dei Cas A, Micheli MM, Aldigeri R, Gardini S, Ferrari-Pellegrini F, Perini M, Messa G, Antonini M, Spigoni V, Cinquegrani G, Vazzana A, Moretti V, Caffarra P, Bonadonna RC (2024) Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. J Endocrinol Invest 47:2339\u20132349","journal-title":"J Endocrinol Invest"},{"key":"8602_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"8602_CR8","doi-asserted-by":"crossref","unstructured":"Edison P, Femminella GD, Ritchie CW, Holmes C, Walker Z, Ridha BH, Raza S, Livingston NR, Nowell J, Busza G, Frangou E, Love S, Williams G, Lawrence RM, McFarlane B, Archer H, Coulthard E, Underwood B, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Williams SCR, Brooks DJ, Harrison JE, Tadros G, Passmore AP, Ballard C (2021) Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia 17","DOI":"10.1002\/alz.057848"},{"key":"8602_CR9","doi-asserted-by":"crossref","unstructured":"Edison PFG, Ritchie CW, Holmes C, Walker Z, Ridha BH, Raza S, Livingston NR, Nowell J, Busza G, Frangou E, Love S, Williams G, Lawrence RM, McFarlane B, Archer H, Coulthard E, Underwood B, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Williams SCR, Brooks DJ, Harrison JE, Tadros G, Passmore AP, Ballard C (2021) Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimer\u2019s and Dementia 17","DOI":"10.1002\/alz.057848"},{"key":"8602_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, Rodell A, Braendgaard H, Gottrup H, Schacht A, Moller N, Brock B, Rungby J (2016) In alzheimer\u2019s Disease, 6-Month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, Placebo-Controlled, Double-Blind clinical trial. Front Aging Neurosci 8:108","journal-title":"Front Aging Neurosci"},{"key":"8602_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNN.0b013e31828b7d26","volume":"26","author":"S Gluhm","year":"2013","unstructured":"Gluhm S, Goldstein J, Loc K, Colt A, Liew CV, Corey-Bloom J (2013) Cognitive performance on the mini-mental state examination and the Montreal cognitive assessment across the healthy adult lifespan. Cogn Behav Neurol 26:1\u20135","journal-title":"Cogn Behav Neurol"},{"key":"8602_CR12","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical, Methods G (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","DOI":"10.1136\/bmj.d5928"},{"key":"8602_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/13854046.2019.1619838","volume":"34","author":"AO Kramer","year":"2020","unstructured":"Kramer AO, Casaletto KB, Umlauf A, Staffaroni AM, Fox E, You M, Kramer JH (2020) Robust normative standards for the California verbal learning test (CVLT) ages 60\u201389: A tool for early detection of memory impairment. Clin Neuropsychol 34:384\u2013405","journal-title":"Clin Neuropsychol"},{"key":"8602_CR14","doi-asserted-by":"publisher","first-page":"937486","DOI":"10.3389\/fnagi.2022.937486","volume":"14","author":"X Li","year":"2022","unstructured":"Li X, Feng X, Sun X, Hou N, Han F, Liu Y (2022) Global, regional, and National burden of alzheimer\u2019s disease and other dementias, 1990\u20132019. Front Aging Neurosci 14:937486","journal-title":"Front Aging Neurosci"},{"key":"8602_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/ADR-230181","volume":"8","author":"Y Liang","year":"2024","unstructured":"Liang Y, Dore V, Rowe CC, Krishnadas N (2024) Clinical evidence for GLP-1 receptor agonists in alzheimer\u2019s disease: A systematic review. J Alzheimers Dis Rep 8:777\u2013789","journal-title":"J Alzheimers Dis Rep"},{"key":"8602_CR16","doi-asserted-by":"crossref","unstructured":"Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A (2022) GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells 11","DOI":"10.3390\/cells11132023"},{"key":"8602_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/1567205016666190913155950","volume":"16","author":"RJ Mullins","year":"2019","unstructured":"Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D (2019) A pilot study of exenatide actions in alzheimer\u2019s disease. Curr Alzheimer Res 16:741\u2013752","journal-title":"Curr Alzheimer Res"},{"key":"8602_CR18","doi-asserted-by":"publisher","first-page":"R741","DOI":"10.1016\/j.cub.2012.07.024","volume":"22","author":"T Niccoli","year":"2012","unstructured":"Niccoli T, Partridge L (2012) Ageing as a risk factor for disease. Curr Biol 22:R741\u2013752","journal-title":"Curr Biol"},{"key":"8602_CR19","doi-asserted-by":"publisher","first-page":"e12268","DOI":"10.1002\/trc2.12268","volume":"8","author":"CH Norgaard","year":"2022","unstructured":"Norgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Moller DV, Knudsen LB, Kvist K, Zinman B, Holm E, Torp-Pedersen C, Morch LS (2022) Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y) 8:e12268","journal-title":"Alzheimers Dement (N Y)"},{"key":"8602_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/sjop.12966","volume":"65","author":"F Ohman","year":"2024","unstructured":"Ohman F, Eckerstrom M, Hessen E, Espenes J, Eliassen IV, Lorentzen IM, Stalhammar J, Kettunen P, Scholl M, Fladby T, Wallin A, Kirsebom BE (2024) Demographically adjusted Rey-Osterrieth complex figure test norms in a Swedish and Norwegian cohort aged 49\u201377 years and comparison with North American norms. Scand J Psychol 65:168\u2013178","journal-title":"Scand J Psychol"},{"key":"8602_CR21","doi-asserted-by":"publisher","first-page":"e39471","DOI":"10.1371\/journal.pone.0039471","volume":"7","author":"K Thorlund","year":"2012","unstructured":"Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, Gluud C, Devereaux PJ, Wetterslev J (2012) Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS ONE 7:e39471","journal-title":"PLoS ONE"},{"key":"8602_CR22","doi-asserted-by":"publisher","first-page":"e3673","DOI":"10.1002\/dmrr.3673","volume":"39","author":"S Tian","year":"2023","unstructured":"Tian S, Jiang J, Wang J, Zhang Z, Miao Y, Ji X, Bi Y (2023) Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis. Diabetes Metab Res Rev 39:e3673","journal-title":"Diabetes Metab Res Rev"},{"key":"8602_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13195-015-0151-0","volume":"7","author":"N Verma","year":"2015","unstructured":"Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK, Alzheimer\u2019s Disease Neuroimaging I (2015) New scoring methodology improves the sensitivity of the alzheimer\u2019s disease assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimers Res Ther 7:64","journal-title":"Alzheimers Res Ther"},{"key":"8602_CR24","doi-asserted-by":"publisher","first-page":"1018027","DOI":"10.3389\/fneur.2022.1018027","volume":"13","author":"XC Wang","year":"2022","unstructured":"Wang XC, Chu CL, Li HC, Lu K, Liu CJ, Cai YF, Quan SJ, Zhang SJ (2022) Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with alzheimer\u2019s disease and mild cognitive impairment: A systematic review and network meta-analysis. Front Neurol 13:1018027","journal-title":"Front Neurol"},{"key":"8602_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL (2019) Neural correlates of liraglutide effects in persons at risk for alzheimer\u2019s disease. Behav Brain Res 356:271\u2013278","journal-title":"Behav Brain Res"},{"key":"8602_CR26","doi-asserted-by":"publisher","first-page":"530219","DOI":"10.3389\/fnins.2020.530219","volume":"14","author":"X Yan","year":"2020","unstructured":"Yan X, Hu Y, Wang B, Wang S, Zhang X (2020) Metabolic dysregulation contributes to the progression of alzheimer\u2019s disease. Front Neurosci 14:530219","journal-title":"Front Neurosci"},{"key":"8602_CR27","doi-asserted-by":"publisher","unstructured":"Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A (2010) Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimer Dement 6(1):1\u201310.e1. https:\/\/doi.org\/10.1016\/j.jalz.2009.10.003","DOI":"10.1016\/j.jalz.2009.10.003"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08602-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:04:17Z","timestamp":1773072257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08602-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["8602"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08602-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was performed solely on previously published data and was therefore carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. Beyond the authors\u2019 primary affiliations, no additional support was provided for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}